CD_(117)在多发性骨髓瘤细胞中的表达及其意义  

Expression of CD_(117) Antigen on Multiple Myeloma and Its Significance

作　　者：李娟[1] 罗绍凯[1] 张国材[1] 洪文德[1] 童秀珍[1] 

机构地区：[1]中山大学附属第一医院血液科,广东广州510080

出　　处：《癌症》2004年第8期951-954,共4页Chinese Journal of Cancer

基　　金：广东省科技计划资助项目(No.2003C30305)~~

摘　　要：背景与目的细胞表面分化抗原CD117是酪氨酸激酶选择性抑制剂作用的靶点之一,细胞表面是否表达CD117及表达的量与酪氨酸激酶选择性抑制剂作用关系密切。本研究探讨CD117在各种多发性骨髓瘤(multiplemyeloma,MM)细胞中的表达,为酪氨酸激酶选择性抑制剂在MM中的应用提供理论依据,同时评价CD117在MM细胞中表达的意义。方法采用CD45/SSC双参数散点图设门方法进行三色流式细胞术测定细胞表面分化抗原CD117、CD56、CD54。结果48例MM患者中有17例(35.50%)瘤细胞CD117表达阳性,39例(81.20%)CD56表达阳性,48例(100.00%)CD54表达阳性,48例MM患者瘤细胞CD117阳性率低于CD56、CD54;CD117阳性率与骨髓中瘤细胞比例呈正相关;CD117在IgG型的MM中阳性率(64.00%)高于其它如轻链型、IgA型MM;CD117阳性率在不同分期、初治或复发难治的MM中差异无显著性(P>0.05,P>0.01);CD117阳性的初治MM患者对VAD化疗方案的反应率(71.43%)与CD117阴性的反应率(66.68%)比较无明显差异(P>0.05)。结论CD117可作为MM的肿瘤相关抗原,也可作为靶向信号转导抑制剂酪氨酸激酶选择性抑制剂应用的有价值的标志。BACKGROUND &OBJECTIVE: Leukocyte differentiation antigen CD117 is one of the targets that tyrosine kinase selective inhibitors work on. Whether CD117 is expressed on the cell surface,and the expression level are highly correlated with tyrosine kinase selective inhibitors. This study was designed to investigate the expression of CD117 on multiple myeloma (MM) cells, which may provide a theoretical evidence for the use of tyrosine kinase selective inhibitors in MM,meanwhile,the importance of CD117 expression on MM cells was estimated. METHODS: CD117, CD56, and CD54 were measured by three color flow cytometry with CD45/SSC gating strategy. RESULTS: Of 48 patients with MM, 17(35.5%) had positive CD117 expression on myeloma cells, 39 (81.2%) had positive CD56 expression, and 48 (100.0%) had positive CD54 expression. CD117 expression on myeloma cells was lower than CD56,and CD54. CD117 positive expression was positive correlated with the percentage of myeloma cells in bone marrow. CD117 positive in IgG type of MM was 64%, higher than other types such as light chain or IgA. CD117 positivity showed no significant difference in different stages (P >0.05), and in patients havent been pretreated, or relapsed after pretreated (P >0.01). In MM patients havent been pretreated, the reaction rate of VAD chemotherapy in CD117 positive cases was 71.4%, and showed no significant difference (P >0.05) compared with the reaction rate of 66.7%in CD117 negative cases. CONCLUSION: CD117 can be regard as the related tumor antigen of MM, and may be a valuable marker in the use of tyrosine kinase selective inhibitors, which inhibit the signal conduct to the target.

关 键 词：多发性骨髓瘤 抗原 CD117 免疫表型 

分 类 号：R733.3[医药卫生—肿瘤]